BeOne Medicines AG DRC (ONC)

Currency in USD
308.91
+0.28(+0.09%)
Closed·
298.57-10.34(-3.35%)
·
ONC Scorecard
Full Analysis
Net income is expected to grow this year
ONC is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
306.35309.68
52 wk Range
170.99330.63
Key Statistics
Prev. Close
308.91
Open
308.84
Day's Range
306.35-309.68
52 wk Range
170.99-330.63
Volume
120.36K
Average Volume (3m)
370.71K
1-Year Change
55.06%
Book Value / Share
31.78
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ONC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
355.84
Upside
+15.19%
Members' Sentiments
Bearish
Bullish
ProTips
5 analysts have revised their earnings upwards for the upcoming period

BeOne Medicines AG DRC News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy

BeOne Medicines AG DRC Company Profile

BeOne Medicines Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; Ociperlimab (BGB-A1217), a TIGIT inhibitor; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines Ltd. in May 2025. BeOne Medicines Ltd. was incorporated in 2010 and is based in Basel, Switzerland.

Compare ONC to Peers and Sector

Metrics to compare
ONC
Peers
Sector
Relationship
P/E Ratio
−191.3x−2.1x−0.5x
PEG Ratio
−2.86−0.200.00
Price/Book
9.0x2.5x2.6x
Price / LTM Sales
7.5x6.3x3.3x
Upside (Analyst Target)
14.9%252.4%38.7%
Fair Value Upside
Unlock9.3%5.0%Unlock

Analyst Ratings

24 Buy
1 Hold
1 Sell
Ratings:
26 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 355.84
(+15.19% Upside)

Earnings

Latest Release
Aug 06, 2025
EPS / Forecast
0.17 / 0.21
Revenue / Forecast
1.32B / 1.24B
EPS Revisions
Last 90 days

ONC Income Statement

People Also Watch

178.56
ALAB
+2.53%
129.05
CRCL
+3.04%
132.17
INSM
+3.00%
36.020
SMR
+0.33%
69.83
MP
-3.43%

FAQ

What Stock Exchange Does BeOne Medicines DRC Trade On?

BeOne Medicines DRC is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for BeOne Medicines DRC?

The stock symbol for BeOne Medicines DRC is "ONC."

What Is the BeOne Medicines DRC Market Cap?

As of today, BeOne Medicines DRC market cap is 35.36B.

What Is BeOne Medicines DRC's Earnings Per Share (TTM)?

The BeOne Medicines DRC EPS (TTM) is -11.91.

When Is the Next BeOne Medicines DRC Earnings Date?

BeOne Medicines DRC will release its next earnings report on 05 Nov 2025.

From a Technical Analysis Perspective, Is ONC a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has BeOne Medicines DRC Stock Split?

BeOne Medicines DRC has split 0 times.

How Many Employees Does BeOne Medicines DRC Have?

BeOne Medicines DRC has 11000 employees.

What is the current trading status of BeOne Medicines DRC (ONC)?

As of 27 Aug 2025, BeOne Medicines DRC (ONC) is trading at a price of 308.91, with a previous close of 308.91. The stock has fluctuated within a day range of 306.35 to 309.68, while its 52-week range spans from 170.99 to 330.63.

What Is BeOne Medicines DRC (ONC) Price Target According to Analysts?

The average 12-month price target for BeOne Medicines DRC is USD355.84083, with a high estimate of USD448 and a low estimate of USD250. 24 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Strong Buy. The stock has an +15.19% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.